HWHG(SH:600079) Shang Hai Zheng Quan Bao·2025-09-16 20:24Core Viewpoint - The approval of Fluorobiphenyl Ester Injection and Levonorgestrel Tablets marks significant advancements for the company in expanding its product pipeline and enhancing its market presence in the pharmaceutical industry [1][4]. Group 1: Fluorobiphenyl Ester Injection - The company’s subsidiary, Yichang Renfu Pharmaceutical, received the drug registration certificate for Fluorobiphenyl Ester Injection from the National Medical Products Administration [1]. - The injection is a non-steroidal analgesic suitable for postoperative and cancer pain management, with a cumulative R&D investment of approximately RMB 35 million [2]. - The projected national sales for Fluorobiphenyl Ester Injection in 2024 are around RMB 980 million, with major competitors including Beijing Tide Pharmaceutical and Wuhan Yanda Medical Nutrition Science [2]. - The approval allows the company to sell the product in the domestic market, which is expected to positively impact its business [2]. Group 2: Levonorgestrel Tablets - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical, received the drug registration certificate for Levonorgestrel Tablets from the National Medical Products Administration [4]. - Levonorgestrel Tablets are indicated for emergency contraception, with a cumulative R&D investment of approximately RMB 13.5 million [5]. - The projected national sales for Levonorgestrel Tablets in 2024 are around RMB 1.14 billion, with key competitors including China Resources Zizhu Pharmaceutical and Gedeon Richter Plc [5]. - The approval signifies the company’s eligibility to market the product domestically, which is anticipated to further enrich its product line and positively influence its financial performance [5].